YY-20394
98%
- Product Code: 109975
CAS:
1702816-75-8
| Molecular Weight: | 588.69 g./mol | Molecular Formula: | C₂₈H₃₇FN₆O₅S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
YY-20394 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a selective inhibitor of PI3Kδ, a key enzyme involved in the PI3K/AKT/mTOR signaling pathway, which plays a critical role in cell growth, survival, and metabolism. By targeting this pathway, YY-20394 shows promise in treating certain types of cancers, particularly hematologic malignancies like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Its selective inhibition of PI3Kδ aims to minimize off-target effects, potentially offering a safer and more effective treatment option compared to broader PI3K inhibitors. Preclinical and clinical studies are ongoing to evaluate its efficacy, safety, and potential as a targeted cancer therapy.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Light Yellow To Yellow Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿47,772.00 |
+
-
|
YY-20394
YY-20394 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a selective inhibitor of PI3Kδ, a key enzyme involved in the PI3K/AKT/mTOR signaling pathway, which plays a critical role in cell growth, survival, and metabolism. By targeting this pathway, YY-20394 shows promise in treating certain types of cancers, particularly hematologic malignancies like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Its selective inhibition of PI3Kδ aims to minimize off-target effects, potentially offering a safer and more effective treatment option compared to broader PI3K inhibitors. Preclinical and clinical studies are ongoing to evaluate its efficacy, safety, and potential as a targeted cancer therapy.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :